MUC1 and neoplasm: An antibody targeting the MUC1-C extracellular domain has been developed as (1) an antibody–drug conjugate that is effective against human TNBC cells growing in vitro and as tumor xenografts,14 46 and (2) a CAR T cell that is entering clinical evaluation, both of which represent potential agents for eliminating MUC1-C-expressing TNBC tumor cells and reversing immune suppression.